Patentability Standards for Follow-on Pharmaceutical Innovation
(2018) In Biotechnology Law Report 37(3). p.131-161- Abstract
- Follow-on pharmaceutical innovation occurring after the initial discovery of a drug active ingredient plays an important, but at times underappreciated, role in providing innovative solutions to compelling medical needs. Examples of follow-on innovation include new forms of a drug with improved safety-efficacy profiles, new formulations and dosages providing improved patient outcomes, and new methods of using an established drug more safely or to treat new indications. Patents play a critical role in incentivizing the research, development, testing, and ultimately commercialization of follow-on pharmaceutical innovation, and in doing so provide substantial benefits for public health and patients' quality of life. There is, however, a body... (More)
- Follow-on pharmaceutical innovation occurring after the initial discovery of a drug active ingredient plays an important, but at times underappreciated, role in providing innovative solutions to compelling medical needs. Examples of follow-on innovation include new forms of a drug with improved safety-efficacy profiles, new formulations and dosages providing improved patient outcomes, and new methods of using an established drug more safely or to treat new indications. Patents play a critical role in incentivizing the research, development, testing, and ultimately commercialization of follow-on pharmaceutical innovation, and in doing so provide substantial benefits for public health and patients' quality of life. There is, however, a body of literature characterizing patents directed towards follow-on innovations as ''secondary pharmaceutical patents.'' Some have even gone so far as to propose that the criteria for patentability should be enforced more stringently with respect to follow-on pharmaceutical inventions as compared to other inventions. The underlying assumption of such proposals is that follow-on pharmaceutical innovations are somehow secondary to other pharmaceutical innovation, and thus less deserving of patent protection. In this article, we refute the notion that follow-on pharmaceutical innovation should be categorically singled out for unfavorable treatment under the patent laws, and provide numerous examples of the value that follow-on innovation brings to medicine, and ultimately to patients. We also propose, in view of the international treaty obligations set out in, inter alia, the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (''TRIPS Agreement''), standards and best practices for assessing the patentability of inventions arising out of follow-on pharmaceutical innovation. These are essentially the same stringent standards applicable to ''primary'' pharmaceutical innovation, and inventions in general. This article provides numerous examples from jurisdictions around the world in which patent offices and courts have applied the well-recognized requirements of patentability, including patent eligibility, novelty, inventive step and industrial application, to follow-on pharmaceutical inventions, and in so doing have advanced innovation in public health and ultimately the lives of patients. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/e5e4225c-da13-423b-8fc9-45bc105096c5
- author
- Holman, Christopher M. ; Minssen, Timo LU and Solovy, Eric M.
- publishing date
- 2018-06-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Patent examination, Patentability guidelines, Pharmaceutical patents, TRIPS agreement, UNDP
- in
- Biotechnology Law Report
- volume
- 37
- issue
- 3
- pages
- 31 pages
- publisher
- Mary Ann Liebert, Inc.
- external identifiers
-
- scopus:85048833231
- ISSN
- 0730-031X
- DOI
- 10.1089/blr.2018.29073.cmh
- language
- English
- LU publication?
- no
- id
- e5e4225c-da13-423b-8fc9-45bc105096c5
- date added to LUP
- 2020-12-16 14:18:37
- date last changed
- 2022-04-03 07:00:00
@article{e5e4225c-da13-423b-8fc9-45bc105096c5,
abstract = {{Follow-on pharmaceutical innovation occurring after the initial discovery of a drug active ingredient plays an important, but at times underappreciated, role in providing innovative solutions to compelling medical needs. Examples of follow-on innovation include new forms of a drug with improved safety-efficacy profiles, new formulations and dosages providing improved patient outcomes, and new methods of using an established drug more safely or to treat new indications. Patents play a critical role in incentivizing the research, development, testing, and ultimately commercialization of follow-on pharmaceutical innovation, and in doing so provide substantial benefits for public health and patients' quality of life. There is, however, a body of literature characterizing patents directed towards follow-on innovations as ''secondary pharmaceutical patents.'' Some have even gone so far as to propose that the criteria for patentability should be enforced more stringently with respect to follow-on pharmaceutical inventions as compared to other inventions. The underlying assumption of such proposals is that follow-on pharmaceutical innovations are somehow secondary to other pharmaceutical innovation, and thus less deserving of patent protection. In this article, we refute the notion that follow-on pharmaceutical innovation should be categorically singled out for unfavorable treatment under the patent laws, and provide numerous examples of the value that follow-on innovation brings to medicine, and ultimately to patients. We also propose, in view of the international treaty obligations set out in, inter alia, the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (''TRIPS Agreement''), standards and best practices for assessing the patentability of inventions arising out of follow-on pharmaceutical innovation. These are essentially the same stringent standards applicable to ''primary'' pharmaceutical innovation, and inventions in general. This article provides numerous examples from jurisdictions around the world in which patent offices and courts have applied the well-recognized requirements of patentability, including patent eligibility, novelty, inventive step and industrial application, to follow-on pharmaceutical inventions, and in so doing have advanced innovation in public health and ultimately the lives of patients.}},
author = {{Holman, Christopher M. and Minssen, Timo and Solovy, Eric M.}},
issn = {{0730-031X}},
keywords = {{Patent examination; Patentability guidelines; Pharmaceutical patents; TRIPS agreement; UNDP}},
language = {{eng}},
month = {{06}},
number = {{3}},
pages = {{131--161}},
publisher = {{Mary Ann Liebert, Inc.}},
series = {{Biotechnology Law Report}},
title = {{Patentability Standards for Follow-on Pharmaceutical Innovation}},
url = {{http://dx.doi.org/10.1089/blr.2018.29073.cmh}},
doi = {{10.1089/blr.2018.29073.cmh}},
volume = {{37}},
year = {{2018}},
}